

CLAIMS

1. A use in an implant for subcutaneous or intradermal injection into fibrous tissue of at least one biodegradable thixotropic compound with pseudoplastic properties, preferably at least one bioresorbable thixotropic compound with pseudoplastic properties, and even more preferably at least one thixotropic compound with pseudoplastic properties based on xanthan gum.
2. An implant for subcutaneous or intradermal injection into fibrous tissue, comprising at least one biodegradable thixotropic compound with pseudoplastic properties, preferably at least one bioresorbable thixotropic compound with pseudoplastic properties, and even more preferably at least one thixotropic compound with pseudoplastic properties based on xanthan gum.
3. An implant for subcutaneous or intradermal injection into fibrous tissue, comprising microparticles of at least one biocompatible ceramic compound in suspension in at least one vector fluid, said implant being characterized in that said microparticles are biodegradable and have a size of from 10 to 80 μm , preferably from 15 to 50 μm , said ceramic compound comprising at least one component chosen from the group formed by tricalcium phosphate (β TCP) and biphasic products (BPC), which comprise HAP and β TCP in variable proportion, said component preferably being β TCP, and in that said vector fluid comprises at least one compound based on hyaluronic acid and at least one biodegradable thixotropic compound with pseudoplastic properties, preferably at least one bioresorbable thixotropic compound with pseudoplastic properties

and even more preferably at least one thixotropic compound with pseudoplastic properties based on xanthan gum.

- 5 4. The injectable implant as claimed in the preceding claim, such that said ceramic compound generally has a specific surface area of from 0.5 m²/g to 100 m²/g and preferably from 2 m²/g to 27 m²/g.
- 10 5. The injectable implant as claimed in either of claims 3 and 4, such that the microparticles are bioresorbable, once the implantation has been made into the fibrous tissue, within a period of 2 to 36 months, preferably from 3 to 24 months and even 15 more preferably from 4 to 18 months.
- 20 6. The injectable implant as claimed in one of claims 3 to 5, such that the microparticles are present in the vector fluid in a weight/volume proportion strictly greater than 0% and less than 15%, and preferably from 2% to 12%.
- 25 7. The injectable implant as claimed in one of claims 3 to 6, such that the vector fluid for the implant is a biocompatible gel and preferably a bioresorbable gel.
- 30 8. The injectable implant as claimed in one of claims 3 to 7, such that the hyaluronic acid-based compound predominantly comprises hyaluronic acid.
- 35 9. The injectable implant as claimed in the preceding claim, such that said hyaluronic acid-based compound comprises hyaluronic acid with a molecular weight of greater than one million daltons and preferably from one million to five million daltons.
10. A process for preparing an injectable implant as

claimed in one of claims 3 to 9, comprising the following steps:

- 5 - a biocompatible ceramic compound in the form of microparticles defined according to claim 1 is prepared in a preliminary step,
- 10 - in another step, independently of the above preliminary step, a solution of a vector fluid comprising at least one hyaluronic acid-based compound and at least one biodegradable thixotropic compound with pseudoplastic properties is prepared,
- 15 - the ceramic compound from the preliminary step is then introduced into the vector fluid from the other step, in a final step, so as to obtain an essentially homogeneous suspension.
- 20 11. The injectable implant as claimed in claim 2 or as claimed in one of claims 3 to 9, which is in the form of a ready-to-use prefilled syringe, a ready-to-use prefilled bottle or a lyophilizate to be reconstituted.
- 25 12. A kit for the extemporaneous use of an injectable implant as claimed in claim 2 or as claimed in one of claims 3 to 9, comprising the ceramic compound in a first part and the vector fluid in a second part.
- 30 13. The use of an injectable implant as claimed in claim 2 or as claimed in one of claims 3 to 9 for filling wrinkles and/or fine lines and/or skin depressions and/or scars, comprising the subcutaneous injection of such an implant.